RPC1063 is an investigational drug.
There have been 13 clinical trials for RPC1063.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 3rd 2013.
The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and Ulcer. The leading clinical trial sponsors are Celgene, Bristol-Myers Squibb, and Celgene Corporation.
There are thirty US patents protecting this investigational drug and four hundred and forty-six international patents.